Antibody

Institute for Protein Innovation Appoints Wei Yang, PhD as Director of Target Discovery and Sharon Klein as Director of Philanthropy

Retrieved on: 
星期二, 六月 26, 2018
Immunology, Immune system, Biology, IPI, Monoclonal antibody, Antibody

BOSTON, June 26, 2018 /PRNewswire/ --Institutefor Protein Innovation (IPI), a non-profit research organization focused on empowering research in protein science and developing open-source monoclonal antibodies, announced today the appointments of Wei Yang, PhD as Director of Target Discovery and Sharon Klein as Director of Philanthropy.

Key Points: 
  • BOSTON, June 26, 2018 /PRNewswire/ --Institutefor Protein Innovation (IPI), a non-profit research organization focused on empowering research in protein science and developing open-source monoclonal antibodies, announced today the appointments of Wei Yang, PhD as Director of Target Discovery and Sharon Klein as Director of Philanthropy.
  • Notably, the platform will leverage the existing protein production and antibody discovery pipelines at IPI.
  • Ms. Klein will direct IPI's fundraising efforts and raise broader awareness of IPI's mission in her new role as Director of Philanthropy.
  • "We are fortunate to have Wei and Sharon join the IPI team as both have remarkable track records," said President Steven Almo, PhD.

Cantargia Obtains Two New Granted Patents in USA for Antibody-based Cancer Therapy Against IL1RAP

Retrieved on: 
星期二, 六月 26, 2018
Monoclonal antibodies, Medicine, Clinical medicine, Immunology, Cancer, RTT, Health, Antibody, United States Patent and Trademark Office

Cantargia develops antibody based pharmaceuticals against IL1RAP.

Key Points: 
  • Cantargia develops antibody based pharmaceuticals against IL1RAP.
  • The lead project CAN04 is currently in clinical development primarily for treatment of non-small cell lung cancer and pancreatic cancer.
  • The USPTO has now notified Cantargia that both patents were granted on 26 June 2018.
  • "The two new granted patents further strengthen Cantargia's solid protection around cancer treatment via antibodies against IL1RAP.

ImaginAb Reconstitutes Japanese Subsidiary

Retrieved on: 
星期五, 六月 22, 2018
Medicine, Immunology, Immune system, Cancer immunotherapy, Antibody, Clinical medicine

LOS ANGELES and TOKYO, June 22, 2018 /PRNewswire/ -- ImaginAb, Inc. announced today new directors of ImaginAb Japan KK, a wholly-owned subsidiary of Los Angeles-based ImaginAb, Inc. Headquartered in Tokyo, the subsidiary's goal is to better realize partnering opportunities with Japanese pharmaceutical companies.

Key Points: 
  • LOS ANGELES and TOKYO, June 22, 2018 /PRNewswire/ -- ImaginAb, Inc. announced today new directors of ImaginAb Japan KK, a wholly-owned subsidiary of Los Angeles-based ImaginAb, Inc. Headquartered in Tokyo, the subsidiary's goal is to better realize partnering opportunities with Japanese pharmaceutical companies.
  • "We look forward to expanding our Japanese presence and building relationships and collaborations with Japanese pharmaceutical companies," said Martyn Coombs.
  • ImaginAb, Inc. is an immuno-oncology company focused on providing actionable insight into the patient selection and treatment progress for cancer immunotherapy, enabling precision medicine.
  • ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body.

PATH and SD BIOSENSOR announce partnership to advance diagnostic test critical for malaria treatment and elimination

Retrieved on: 
星期三, 六月 20, 2018
Medicine, Biology, Immunologic tests, Clinical medicine, Biosensors, Biotechnology, Biochemistry methods, Glucose-6-phosphate dehydrogenase, Immunoassay, Antibody

As part of this work, PATH partnered with SD BIOSENSOR to develop and evaluate a new diagnostic for G6PD deficiency.

Key Points: 
  • As part of this work, PATH partnered with SD BIOSENSOR to develop and evaluate a new diagnostic for G6PD deficiency.
  • "The strength of the partnership resides in SD BIOSENSOR's commitment to making the test available and affordable for malaria-endemic settings."
  • SD BIOSENSOR has CE marked the STANDARD G6PD Test to conform with the European Union IVD Directive (98/79/EC) and the test is currently undergoing further clinical evaluations.
  • At SD BIOSENSOR, we provide diagnostic products of excellent quality by developing fluorescence immunoassay products that can perform qualitative as well as quantitative results using antigen and antibody responses.

Documentary on Cell Line Authentication Released by Biocompare

Retrieved on: 
星期二, 六月 19, 2018
Biology, Cell culture, Computer access control, Cellular senescence, Cell biology, Authentication, Notary, Packaging, Immortalised cell line, Reproducibility, Medicine, Antibody

SOUTH SAN FRANCISCO, Calif., June 19, 2018 /PRNewswire/ -- "The Importance of Cell Line Authentication", a documentary produced by Biocompare in collaboration with an international team of scientific leaders, is now available for viewing.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 19, 2018 /PRNewswire/ -- "The Importance of Cell Line Authentication", a documentary produced by Biocompare in collaboration with an international team of scientific leaders, is now available for viewing.
  • The documentary is focused on misidentified and contaminated cell lines, which are at the crux of the reproducibility crisis plaguing scientific research.
  • The accuracy and reliability of all biomedical research is in jeopardy, and it is clear that cell line authentication is imperative.
  • After our last film on " Antibody Validation Challenges " we felt that Cell Line Authentication was an obvious topic for a follow up.

Single-use Bioprocessing Market Size Worth $26.89 Billion by 2025: Grand View Research, Inc.

Retrieved on: 
星期二, 六月 19, 2018
Biology, Immunology, Biotechnology, Immune system, Monoclonal antibody, Bioprocess, Antibody, Monoclonal

The global single-use bioprocessing market size is expected to reach USD 26.89 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 13.6% during the forecast period.

Key Points: 
  • The global single-use bioprocessing market size is expected to reach USD 26.89 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 13.6% during the forecast period.
  • Browse related reports by Grand View Research:
    Monoclonal Antibodies (mAbs) Market - The global monoclonal antibodies (mAbs) market accounted for USD 85.4 billion in 2015.
  • Vascular Closure Device (VCD) Market - The Global Vascular Closure Device (VCDs) market was valued at USD over 1.0 billion in 2015.
  • Grand View Research has segmented the global single-use bioprocessing market on the basis of product, workflow, end use, and region:
    Single-use Bioprocessing Product Outlook (Revenue, USD Billion, 2014 - 2025)

2018 TCR-Based Antibody and T-Cell Immunotherapy Report Package: Two Full Reports Covering TCR-based T-cell and Recombinant Antibody (Fusion Protein) Immunotherapy of Cancer

Retrieved on: 
星期四, 六月 14, 2018
Medicine, Immunology, Clinical medicine, Immune system, T cells, Chimeric antigen receptor, Gene therapy, Monoclonal antibody, Cancer immunotherapy, T-cell receptor, Antibody, Fusion protein

The "Report Package: TCR-Based Antibody and T-Cell Immunotherapy" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Report Package: TCR-Based Antibody and T-Cell Immunotherapy" report has been added to ResearchAndMarkets.com's offering.
  • T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics.
  • However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy.
  • This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

Trianni, Inc. Signs Licensing Agreement with Straterx, Inc.

Retrieved on: 
星期二, 六月 12, 2018
Medicine, Immunology, Biology, Immune system, Clinical medicine, Monoclonal antibodies, Biotechnology, Antibody, Tanox, Antibody Solutions

"The Trianni Mouse is notably the best available antibody discovery platform," mentioned Dr. Matthew Taylor, president of Straterx.

Key Points: 
  • "The Trianni Mouse is notably the best available antibody discovery platform," mentioned Dr. Matthew Taylor, president of Straterx.
  • "I'm excited to work with TRIANNI to develop highly effective therapeutic monoclonal antibodies."
  • Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology.
  • Additional information about TRIANNIis available through its corporate website, www.trianni.com .

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease

Retrieved on: 
星期二, 六月 12, 2018
Medicine, Biology, Monoclonal antibodies, Immunology, Health, Neurological disorders, Immune system, Antivirals, Monoclonal antibody therapy, Neurodegeneration, Antibody, Amyloid

Selexis, SA will carry out this critical first step in the manufacturing of antibody therapeutics using the proprietary Selexis SUREtechnologyPlatform.

Key Points: 
  • Selexis, SA will carry out this critical first step in the manufacturing of antibody therapeutics using the proprietary Selexis SUREtechnologyPlatform.
  • ProMIS' lead antibody product candidate, PMN310, is a humanized antibody that binds with high affinity and selectivity for the toxic oligomers of amyloid beta (A), a recognized root cause of AD.
  • ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
  • Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.

Neuroprotective Agents: Therapeutic Applications and Global Markets

Retrieved on: 
星期一, 六月 11, 2018
Medicine, Clinical medicine, Biology, Immunology, Neurology, Monoclonal antibodies, Neuroprotection, Monoclonal antibody therapy, Small molecule, Erythropoietin, Antibody

The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.

Key Points: 
  • The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.
  • Neuroprotective agents in global markets and clinical pipelines include small molecule drugs, therapeutic monoclonal antibodies, gene therapies, cell therapies and other agents.
  • The global market for neuroprotective agents was valued at $REDACTED billion in 2016 and $REDACTED billion.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.